Stocktoria
ARVINAS, INC. ARVN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-09-27
ARVINAS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M | $131.4M | $53.6M |
| R&D expense | $285.2M | $348.2M | $379.7M | $315.0M | $180.4M |
| Operating income | -$118.5M | -$250.2M | -$401.5M | -$263.2M | -$188.4M |
| Interest expense | — | $0 | $0 | $0 | $0 |
| Income tax | $300,000 | $600,000 | $900,000 | $20.9M | $0 |
| Net income | -$80.8M | -$198.9M | -$367.3M | -$282.5M | -$191.0M |
| EPS (diluted) | $-1.14 | $-2.77 | $-6.62 | $-5.31 | $-3.82 |
| Operating cash flow | -$273.8M | -$259.3M | -$347.8M | -$273.5M | $559.4M |
| Free cash flow | -$275.7M | -$261.1M | -$350.7M | -$280.3M | $554.7M |
| Cash & equivalents | $142.9M | $100.5M | $311.7M | $81.3M | $108.3M |
| Total assets | $717.9M | $1.1B | $1.3B | $1.3B | $1.6B |
| Total liabilities | $284.0M | $529.7M | $644.6M | $703.9M | $799.9M |
| Shareholders' equity | $433.9M | $561.7M | $660.0M | $564.9M | $781.7M |
Source: SEC EDGAR filings · CIK 0001655759 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.